Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Sarcopenia | Research

Red blood cell distribution width is associated with sarcopenia risk in early-stage non-small cell lung cancer

Authors: Qing-chun Jia, Ling Qin, Ye Niu, Le Liu, Ping-ping Liu, Shi-di Miao, Ming-ming Cui, Rui-tao Wang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Sarcopenia has received increasing attention in non-small cell lung cancer (NSCLC). Red blood cell distribution width (RDW) is a significant component of the complete blood count and indicates the heterogeneity of erythrocyte volume. Little information is known about RDW in relation to sarcopenia in early-stage (IA-IIIA) NSCLC. The purpose of the present study was to investigate the association between RDW and sarcopenia risk in early-stage NSCLC patients.

Methods

This study included 378 patients with pathologically confirmed stage IA-IIIA NSCLC. Sarcopenia was defined by measuring the skeletal muscle index (SMI) at the eleventh thoracic vertebra level. The maximum Youden index on the receiver operating characteristic (ROC) curve was used to estimate the cutoff value for RDW to predict sarcopenia. Logistic regression analyses were carried out to assess the independent risk factors for sarcopenia in NSCLC.

Results

The ROC curve indicated that the best cutoff point for RDW to predict sarcopenia was 12.9 (sensitivity of 43.80% and specificity of 76.76%, respectively). Moreover, there were significant differences in hemoglobin (p < 0.001), comorbidities (p = 0.001), histological type (p = 0.002), and cancer stage (p = 0.032) between the high RDW and low RDW groups. Logistic regression analyses revealed that high RDW is an independent risk factor for sarcopenia in early-stage NSCLC.

Conclusion

RDW is associated with sarcopenia risk in early-stage NSCLC.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.CrossRef
2.
go back to reference Li C, Zhang L, Meng G, Wang Q, Lv X, Zhang J, et al. Circular RNAs: pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non-small cell lung cancer. J Cancer Res Clin Oncol. 2019;145(12):2875–89.CrossRefPubMed Li C, Zhang L, Meng G, Wang Q, Lv X, Zhang J, et al. Circular RNAs: pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non-small cell lung cancer. J Cancer Res Clin Oncol. 2019;145(12):2875–89.CrossRefPubMed
3.
go back to reference Anderson LJ, Albrecht ED, Garcia JM. Update on management of cancer-related cachexia. Curr Oncol Rep. 2017;19(1):3.CrossRefPubMed Anderson LJ, Albrecht ED, Garcia JM. Update on management of cancer-related cachexia. Curr Oncol Rep. 2017;19(1):3.CrossRefPubMed
4.
go back to reference Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–23.CrossRefPubMedPubMedCentral Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–23.CrossRefPubMedPubMedCentral
5.
go back to reference Cortellini A, Palumbo P, Porzio G, Verna L, Giordano AV, Masciocchi C, et al. Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. Thorac Cancer. 2018;9(12):1623–30.CrossRefPubMedPubMedCentral Cortellini A, Palumbo P, Porzio G, Verna L, Giordano AV, Masciocchi C, et al. Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. Thorac Cancer. 2018;9(12):1623–30.CrossRefPubMedPubMedCentral
6.
go back to reference Takamori S, Tagawa T, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, et al. Prognostic impact of postoperative skeletal muscle decrease in non-small cell lung cancer. Ann Thorac Surg. 2020;109(3):914–20.CrossRefPubMed Takamori S, Tagawa T, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, et al. Prognostic impact of postoperative skeletal muscle decrease in non-small cell lung cancer. Ann Thorac Surg. 2020;109(3):914–20.CrossRefPubMed
7.
go back to reference Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (Bethesda Md: 1985). 2004;97(6):2333–8.CrossRef Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (Bethesda Md: 1985). 2004;97(6):2333–8.CrossRef
8.
go back to reference Derstine BA, Holcombe SA, Ross BE, Wang NC, Su GL, Wang SC. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep. 2018;8(1):11369.CrossRefPubMedPubMedCentral Derstine BA, Holcombe SA, Ross BE, Wang NC, Su GL, Wang SC. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep. 2018;8(1):11369.CrossRefPubMedPubMedCentral
9.
go back to reference Förhécz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohászka Z, Jánoskuti L. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am Heart J. 2009;158(4):659–66.CrossRefPubMed Förhécz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohászka Z, Jánoskuti L. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am Heart J. 2009;158(4):659–66.CrossRefPubMed
10.
go back to reference Ma C, Wang X, Zhao R. Associations of lymphocyte percentage and red blood cell distribution width with risk of lung cancer. J Int Med Res. 2019;47(7):3099–108.CrossRefPubMedPubMedCentral Ma C, Wang X, Zhao R. Associations of lymphocyte percentage and red blood cell distribution width with risk of lung cancer. J Int Med Res. 2019;47(7):3099–108.CrossRefPubMedPubMedCentral
11.
go back to reference Toyokawa G, Shoji F, Yamazaki K, Shimokawa M, Takeo S. Significance of the red blood cell distribution width in resected pathologic stage I nonsmall cell lung cancer. Semin Thorac Cardiovasc Surg. 2020;32(4):1036–45.CrossRefPubMed Toyokawa G, Shoji F, Yamazaki K, Shimokawa M, Takeo S. Significance of the red blood cell distribution width in resected pathologic stage I nonsmall cell lung cancer. Semin Thorac Cardiovasc Surg. 2020;32(4):1036–45.CrossRefPubMed
12.
go back to reference Koma Y, Onishi A, Matsuoka H, Oda N, Yokota N, Matsumoto Y, et al. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. PLoS One. 2013;8(11):e80240. Koma Y, Onishi A, Matsuoka H, Oda N, Yokota N, Matsumoto Y, et al. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. PLoS One. 2013;8(11):e80240.
13.
go back to reference Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: a simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52(2):86–105.CrossRefPubMed Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: a simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52(2):86–105.CrossRefPubMed
14.
go back to reference Onodera T, Goseki N, Kosaki G. [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi. 1984;85(9):1001–5.PubMed Onodera T, Goseki N, Kosaki G. [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi. 1984;85(9):1001–5.PubMed
15.
go back to reference Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Kitamura A, Ichikawa T, et al. Close relationship between immunological/inflammatory markers and myopenia and myosteatosis in patients with colorectal cancer: a propensity score matching analysis. JPEN J Parenter Enter Nutr. 2019;43(4):508–15.CrossRef Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Kitamura A, Ichikawa T, et al. Close relationship between immunological/inflammatory markers and myopenia and myosteatosis in patients with colorectal cancer: a propensity score matching analysis. JPEN J Parenter Enter Nutr. 2019;43(4):508–15.CrossRef
16.
go back to reference Lee JK, Park YS, Lee K, Youn SI, Won Y, Min SH, et al. Prognostic significance of surgery-induced Sarcopenia in the survival of gastric cancer patients: a sex-specific analysis. J Cachexia Sarcopenia Muscle. 2021;12(6):1897–907.CrossRefPubMedPubMedCentral Lee JK, Park YS, Lee K, Youn SI, Won Y, Min SH, et al. Prognostic significance of surgery-induced Sarcopenia in the survival of gastric cancer patients: a sex-specific analysis. J Cachexia Sarcopenia Muscle. 2021;12(6):1897–907.CrossRefPubMedPubMedCentral
17.
go back to reference Huang CY, Yang YC, Chen TC, Chen JR, Chen YJ, Wu MH, et al. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer. J Cachexia Sarcopenia Muscle. 2020;11(2):534–46.CrossRefPubMedPubMedCentral Huang CY, Yang YC, Chen TC, Chen JR, Chen YJ, Wu MH, et al. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer. J Cachexia Sarcopenia Muscle. 2020;11(2):534–46.CrossRefPubMedPubMedCentral
18.
go back to reference Choi MH, Yoon SB, Lee K, Song M, Lee IS, Lee MA, et al. Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. J Cachexia Sarcopenia Muscle. 2018;9(2):326–34.CrossRefPubMedPubMedCentral Choi MH, Yoon SB, Lee K, Song M, Lee IS, Lee MA, et al. Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. J Cachexia Sarcopenia Muscle. 2018;9(2):326–34.CrossRefPubMedPubMedCentral
19.
go back to reference Singh R, Mishra MK, Aggarwal H. Inflammation, immunity, and Cancer. Mediat Inflamm. 2017;2017:6027305.CrossRef Singh R, Mishra MK, Aggarwal H. Inflammation, immunity, and Cancer. Mediat Inflamm. 2017;2017:6027305.CrossRef
20.
go back to reference Kim J, Im JS, Choi CH, Park CH, Lee JI, Son KH, et al. The association between red blood cell distribution width and sarcopenia in U.S. adults. Sci Rep. 2018;8(1):11484.CrossRefPubMedPubMedCentral Kim J, Im JS, Choi CH, Park CH, Lee JI, Son KH, et al. The association between red blood cell distribution width and sarcopenia in U.S. adults. Sci Rep. 2018;8(1):11484.CrossRefPubMedPubMedCentral
21.
go back to reference Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys Williams G, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59(3):242–8.CrossRefPubMed Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys Williams G, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59(3):242–8.CrossRefPubMed
22.
go back to reference He Y, Liu C, Zeng Z, Ye W, Lin J, Ou Q. Red blood cell distribution width: a potential laboratory parameter for monitoring inflammation in rheumatoid arthritis. Clin Rheumatol. 2018;37(1):161–7.CrossRefPubMed He Y, Liu C, Zeng Z, Ye W, Lin J, Ou Q. Red blood cell distribution width: a potential laboratory parameter for monitoring inflammation in rheumatoid arthritis. Clin Rheumatol. 2018;37(1):161–7.CrossRefPubMed
23.
go back to reference Tuttle CSL, Thang LAN, Maier AB. Markers of inflammation and their association with muscle strength and mass: a systematic review and meta-analysis. Ageing Res Rev. 2020;64:101185. Tuttle CSL, Thang LAN, Maier AB. Markers of inflammation and their association with muscle strength and mass: a systematic review and meta-analysis. Ageing Res Rev. 2020;64:101185.
24.
go back to reference Bester J, Pretorius E. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Sci Rep. 2016;6:32188. Bester J, Pretorius E. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Sci Rep. 2016;6:32188.
25.
go back to reference Loprinzi PD, Loenneke JP, Abe T. The association between muscle strengthening activities and red blood cell distribution width among a national sample of U.S. adults. Prev Med. 2015;73:130–2.CrossRefPubMed Loprinzi PD, Loenneke JP, Abe T. The association between muscle strengthening activities and red blood cell distribution width among a national sample of U.S. adults. Prev Med. 2015;73:130–2.CrossRefPubMed
26.
go back to reference Chi G, Lee JJ, Montazerin SM, Marszalek J. Prognostic value of hemoglobin-to-red cell distribution width ratio in cancer: a systematic review and meta-analysis. Biomark Med. 2022;16(6):473–82.CrossRefPubMed Chi G, Lee JJ, Montazerin SM, Marszalek J. Prognostic value of hemoglobin-to-red cell distribution width ratio in cancer: a systematic review and meta-analysis. Biomark Med. 2022;16(6):473–82.CrossRefPubMed
27.
go back to reference Wu LC, Kao HH, Chen HJ, Huang PF. Preliminary screening for Sarcopenia and related risk factors among the elderly. Medicine. 2021;100(19):e25946. Wu LC, Kao HH, Chen HJ, Huang PF. Preliminary screening for Sarcopenia and related risk factors among the elderly. Medicine. 2021;100(19):e25946.
28.
go back to reference Chatzipetrou V, Bégin MJ, Hars M, Trombetti A. Sarcopenia in chronic kidney disease: a scoping review of prevalence, risk factors, association with outcomes, and treatment. Calcif Tissue Int. 2022;110(1):1–31.CrossRefPubMed Chatzipetrou V, Bégin MJ, Hars M, Trombetti A. Sarcopenia in chronic kidney disease: a scoping review of prevalence, risk factors, association with outcomes, and treatment. Calcif Tissue Int. 2022;110(1):1–31.CrossRefPubMed
29.
go back to reference Borges TC, Gomes TL, Pichard C, Laviano A, Pimentel GD. High neutrophil to lymphocytes ratio is associated with Sarcopenia risk in hospitalized cancer patients. Clin Nutr. 2021;40(1):202–6.CrossRefPubMed Borges TC, Gomes TL, Pichard C, Laviano A, Pimentel GD. High neutrophil to lymphocytes ratio is associated with Sarcopenia risk in hospitalized cancer patients. Clin Nutr. 2021;40(1):202–6.CrossRefPubMed
30.
go back to reference Lee HS, Koh IH, Kim HS, Kwon YJ. Platelet and white blood cell count are independently associated with sarcopenia: a nationwide population-based study. Thromb Res. 2019;183:36–44.CrossRefPubMed Lee HS, Koh IH, Kim HS, Kwon YJ. Platelet and white blood cell count are independently associated with sarcopenia: a nationwide population-based study. Thromb Res. 2019;183:36–44.CrossRefPubMed
31.
go back to reference Lin J, Zhang W, Huang Y, Chen W, Wu R, Chen X, et al. Sarcopenia is associated with the neutrophil/lymphocyte and platelet/lymphocyte ratios in operable gastric cancer patients: a prospective study. Cancer Manage Res. 2018;10:4935–44.CrossRef Lin J, Zhang W, Huang Y, Chen W, Wu R, Chen X, et al. Sarcopenia is associated with the neutrophil/lymphocyte and platelet/lymphocyte ratios in operable gastric cancer patients: a prospective study. Cancer Manage Res. 2018;10:4935–44.CrossRef
Metadata
Title
Red blood cell distribution width is associated with sarcopenia risk in early-stage non-small cell lung cancer
Authors
Qing-chun Jia
Ling Qin
Ye Niu
Le Liu
Ping-ping Liu
Shi-di Miao
Ming-ming Cui
Rui-tao Wang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11864-z

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine